Malcolm Salter
Director/Board Member at C4 THERAPEUTICS, INC.
Net worth: 92 975 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kenneth Anderson | M | 72 |
Raqia Therapeutics, Inc.
NextRNA Therapeutics, Inc.
 NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 9 years |
| Christopher Bahl | M | - |
AI Proteins, Inc.
 AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 3 years |
| Kendra Adams | F | 48 | 4 years | |
| William McKee | M | 62 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 2 years |
| Bruce Downey | M | 76 | 9 years | |
| Alain J. Cohen | M | 57 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 8 years |
| Andrew Hirsch | M | 53 | 4 years | |
| Drew Dennison | M | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 3 years |
| Elena Prokupets | M | 69 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 8 years |
| Noah Beerman | M | 62 |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 1 years |
| Bihua Chen | F | 55 | 9 years | |
| Julia Novina | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Dominique Verhelle | M | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Bobby Sandage | M | 70 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | - |
| Donna Grogan | M | 67 | 2 years | |
| Glenn Dubin | M | 67 | 3 years | |
| Owen Hughes | M | 49 | 1 years | |
| Laura Bessen | M | 61 | 2 years | |
| Carl Novina | M | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Jolie Siegel | F | 47 | 4 years | |
| Utpal Koppikar | M | 53 | 2 years | |
| Jay Galeota | M | 57 |
Harvard Business School
| - |
| Galya Frayman Molinas | F | - |
Harvard Business School
| - |
| Peter Boyce | M | - |
Harvard Business School
| 4 years |
| Jennifer E. Lum | F | - |
Harvard Business School
| 5 years |
| Cathleen Benko | F | 66 |
Harvard Business School
| - |
| Courtney Solberg | F | - | - | |
| Rana El-Kaliouby | M | 46 |
Harvard Business School
| 3 years |
| Diego du Monceau de Bergendal | M | 75 |
Harvard Business School
| 18 years |
| Naina Lal Kidwai | F | 67 |
Harvard Business School
| - |
| Vikram Gandhi | M | 61 |
Harvard Business School
| - |
| Lindsey Macleod | F | - |
Harvard Business School
| 4 years |
| Frances Frei | M | 60 |
Harvard Business School
| 26 years |
| Dante Roscini | M | 64 |
Harvard Business School
| - |
| Christine Henderson | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
| Joseph Chiedu Keshi | M | - |
Harvard Business School
| - |
| Elizabeth Tempesta | F | - |
Harvard Business School
| - |
| Leonard Reyno | M | 61 | 1 years | |
| Nasser bin Abu Bakar | M | 57 |
Harvard Business School
| - |
| Yumiko Murakami | F | 59 |
Harvard Business School
| 9 years |
| Kulin Sanjay Lalbhai | M | 38 |
Harvard Business School
| - |
| Guhan Subramanian | M | 53 |
Harvard Business School
| - |
| Max H. Bazerman | M | 68 |
Harvard Business School
| 24 years |
| Maya Hari | F | 46 |
Harvard Business School
| - |
| Tarun Khanna | M | 57 |
Harvard Business School
| 31 years |
| David Sin | M | 45 |
Harvard Business School
| - |
| Warnasooriya Fonseka | M | - |
Harvard Business School
| - |
| Vikram Swinder Gandhi | M | - |
Harvard Business School
| - |
| Boris Groysberg | M | 52 |
Harvard Business School
| - |
| Rajiv Lal | M | - |
Harvard Business School
| - |
| Anita Elberse | M | 51 |
Harvard Business School
| - |
| Gary Pisano | M | 62 |
Harvard Business School
| 36 years |
| Bruce Evans | M | 64 |
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | - |
| Curtis Yates Arledge | M | 58 |
Harvard Business School
| 8 years |
| George Riedel | M | 66 |
Harvard Business School
| - |
| David Bruce Yoffie | M | 68 |
Harvard Business School
| 43 years |
| Jim Breyer | M | 62 |
Harvard Business School
| - |
| Royce Yudkoff | M | 68 |
Harvard Business School
| - |
| Kevin Sharer | M | 76 |
Harvard Business School
| - |
| Jamie Dimon | M | 68 |
Harvard Business School
| - |
| Steven S. Rogers | M | 66 |
Harvard Business School
| - |
| Cynthia Ann Montgomery | F | 72 |
Harvard Business School
| 35 years |
| Debora Spar | M | 60 |
Harvard Business School
| 33 years |
| Youngme Moon | M | 60 |
Harvard Business School
| 26 years |
| Joseph Fuller | M | 67 |
Harvard Business School
| 12 years |
| Benjamin Esty | M | 61 |
Harvard Business School
| 31 years |
| Henry McGee | M | 71 |
Harvard Business School
| 11 years |
| Nancy F. Koehn | M | 63 |
Harvard Business School
| 35 years |
| Lee Styslinger | M | 63 |
Harvard Business School
| 12 years |
| John Quelch | M | 73 |
Harvard Business School
| 23 years |
| Willy Shih | M | 73 |
Harvard Business School
| 17 years |
| Michael Porter | M | 76 |
Harvard Business School
| 51 years |
| Joshua Harris | M | 59 |
Harvard Business School
| - |
| J. Cline | M | 64 |
Harvard Business School
| - |
| Abigail Johnson | F | 62 |
Harvard Business School
| - |
| Yusuke Yasuda | M | - |
Harvard Business School
| - |
| Ralph Clark | M | 65 |
Harvard Business School
| - |
| Das Narayandas | M | 63 |
Harvard Business School
| 30 years |
| Imogen Mkhize | F | 61 |
Harvard Business School
| - |
| Byung-Ju Kim | M | 60 |
Harvard Business School
| - |
| Anil Bhavarlal Jain | M | 59 |
Harvard Business School
| - |
| Marco Iansiti | M | 61 |
Harvard Business School
| - |
| Mark Schwartz | M | 69 |
Harvard Business School
| - |
| Malcolm Baker | M | 54 |
Harvard Business School
| - |
| Anne Dias-Griffin | F | 53 |
Harvard Business School
| - |
| Elizabeth Filkin | F | 82 |
Harvard Business School
| - |
| Joseph Bower | M | 85 |
Harvard Business School
| 61 years |
| Archie Jones | M | 52 |
Harvard Business School
| - |
| Rohinton Kalifa | M | 62 |
Harvard Business School
| 5 years |
| Jon Didrik Jonsson | M | 61 |
Harvard Business School
| - |
| Gail Maderis | F | 66 |
Harvard Business School
| - |
| Douglas Grissom | M | 56 |
Harvard Business School
| - |
| Srikant T. Madhav Datar | M | 70 |
Harvard Business School
| 28 years |
| Peter Barrett | M | 71 |
Harvard Business School
| - |
| Kathryn E. Giusti | F | 65 |
Harvard Business School
| 8 years |
| Bader Almana | M | - |
Harvard Business School
| 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Marc A. Cohen | M | 61 |
Raqia Therapeutics, Inc.
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021.
AI Proteins, Inc.
AI Proteins, Inc. Pharmaceuticals: MajorHealth Technology AI Proteins, Inc. is a biotech company based in Andover, MA. AI Proteins is focused on re-imagining protein therapeutics by designing entirely new proteins using an AI-based approach and a high-throughput drug discovery platform. The company's platform enables the development of inexpensive, durable, and highly specific proteins optimized for specific therapeutic applications. These proteins have the potential for oral delivery and can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. The company was founded by Marc A. Cohen and Christopher Bahl. Noah D. Beerman has been the CEO of the company since 2023. | 7 years |
| Jason S. Fisherman | M | 67 | - | |
| Andrew Phillips | M | 53 | 4 years | |
| Lauren White | F | 45 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Malcolm Salter
- Personal Network
